Foundayo Cost Without Insurance vs PlexusDx (2026)

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Foundayo (orforglipron) is Eli Lilly's oral GLP-1 pill, and its cash-pay sticker price — $149/month at the starter dose — has dominated the headlines. The trouble is that $149 is the dose-one price, not the maintenance price. Once a patient escalates to 5.5 mg, 9 mg, or the 14.5 mg / 17.2 mg target doses, the real Self-Pay Savings Card price climbs to $299–$349 per fill, and a 45-day refill window separates the purchase-offer price from the regular price at the two highest doses. That math, plus the 10-fill annual cap and the 12/31/2026 card expiration, decides whether Foundayo without insurance is a $1,800 year or a $3,700 year. This article walks the cash-pay structure, the annual budget by dose path, and where the PlexusDx Microdose GLP-1 Protocol, Semaglutide Oral, and Tirzepatide Oral sit relative to a year of Foundayo — because the choice between branded oral GLP-1 and compounded cash-pay alternatives is rarely about effectiveness of the active ingredient. It's about pricing structure, supply consistency, and whether your dose is anchored to your genetics before week one.

Foundayo without insurance: the dose-by-dose price structure

Foundayo uses a tiered Self-Pay Savings Card price that scales with dose. The 0.8 mg starter is $149/month for month one. 2.5 mg is $199/month, typically month two. 5.5 mg and 9 mg are $299/month each — the maintenance band most patients land on. The two highest doses, 14.5 mg and 17.2 mg, are listed at $349/month at the regular self-pay price, but Lilly's purchase offer holds them at $299/month if you refill within 45 days of your previous fill. Miss the 45-day window at 14.5 mg or 17.2 mg and the price reverts to $349 — a $50 penalty per fill that compounds across the year. The Self-Pay Savings Card itself is free to activate at foundayo.lilly.com but caps you at 10 fills per calendar year, expires 12/31/2026, and is the only mechanism that keeps Foundayo in the $149-$289/mo cash-pay range. Without it, you pay full list price. That's the headline that needs context: the $149 is real for one month; the $299–$349 band is what most patients budget against for the rest of the year.

The 45-day refill rule and the 10-fill annual cap

The 45-day refill rule only applies to the 14.5 mg and 17.2 mg doses, but those are the doses most patients reach by month five or six on a standard escalation. Refilling within 45 days of the prior fill keeps the price at $299; missing the window once costs $50, and missing it three times across a year costs $150. The 10-fill annual cap matters separately — if you start in April 2026, you can fill ten times before the card expires on 12/31/2026, which means a 12-month run can leave you paying full list price for two months unless the program is renewed. As of this writing, 2027 Self-Pay Savings Card terms have not been announced. Compared to PlexusDx Weight Management Protocols, where pricing is published per protocol with no refill-window penalty and no annual fill cap, the Foundayo budget requires more calendar discipline. The PlexusDx Microdose GLP-1 Protocol at $129/mo flat, Semaglutide Oral at $249/mo and up, and Tirzepatide Oral at $279/mo all bill on a clean monthly cadence with no purchase-offer mechanic to track.

The real 12-month cost of Foundayo without insurance

On a standard escalation — 0.8 mg in month one, 2.5 mg in month two, 5.5 mg in month three, 9 mg in month four, then 14.5 mg or 17.2 mg from month five forward — the medication-only total for fills one through six runs about $1,544 with on-time refills and the purchase offer maintained. Fills seven through twelve at $299/fill add roughly $1,794, bringing the 12-fill projection to about $3,338. If a patient misses one 45-day window, add $50; if the patient never qualifies for the purchase offer at high doses, the 12-month projection rises to about $3,738. The headline gap matters: a patient who budgets the $149/month starter price across all twelve months would plan for $1,788, leaving them roughly $1,550 short of the realistic 12-month total. By contrast, a year on the PlexusDx Microdose GLP-1 Protocol is $1,548 flat ($129 × 12), a year on Semaglutide Oral at the entry tier is about $2,508 ($209 × 12), and the year-long total of Tirzepatide Oral ranges from $2,748 to $6,108 depending on dose level — with no 45-day refill penalty, no 10-fill cap, and no purchase-offer expiration to navigate.

Cash-pay alternatives to Foundayo: PlexusDx pricing by mechanism

If Foundayo's structure doesn't fit — whether because you want a flatter monthly bill, a different mechanism, or compounded medication priced beneath the $299–$349 maintenance band — PlexusDx Weight Management Protocols offer six cash-pay options across four mechanism classes, all-inclusive of async provider consultation, prescription, compounded medication, and shipping. The Microdose GLP-1 Protocol is $129/mo flat with four delivery variants (capsule, troche, lozenge, sublingual) for patients who want needle-free, low-dose GLP-1. Semaglutide Oral at $249/mo and up gives a daily pill across six dose levels (3 mg to 24 mg). Semaglutide Injection at $149/mo is the weekly compounded counterpart to Wegovy and Ozempic. Tirzepatide Injection at $249/mo is the weekly dual-agonist counterpart to Zepbound and Mounjaro. Tirzepatide Oral at $279/mo offers seven daily-pill dose levels for patients who want dual-mechanism therapy without an injection. GLP-Squared at $249/mo is a compounded semaglutide-plus-tirzepatide stack across six provider-titrated dose pairs. PlexusDx is cash-pay in all 50 states with no membership fee; five states require a scheduled live consultation rather than async intake.

Compounded vs branded: what you're actually buying

Foundayo is an FDA-approved finished drug product — the same orforglipron that ran the ATTAIN-1 clinical trial, dispensed as a branded medication through LillyDirect, Amazon Pharmacy, GoodRx, or a partner telehealth provider like Ro. PlexusDx Weight Management Protocols dispense compounded semaglutide and tirzepatide prepared by licensed U.S. compounding pharmacies. Compounded semaglutide and tirzepatide are not FDA-approved finished drug products; they are pharmacy-prepared versions of the same active ingredients found in Wegovy, Ozempic, Mounjaro, and Zepbound. The boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies, and the FDA-labeled side-effect profile — nausea, vomiting, diarrhea, constipation, abdominal pain, headache, with less common but documented pancreatitis, gallbladder disease, and acute kidney injury — characterizes the GLP-1 receptor agonist class as a whole. The branded vs compounded choice is not about the active ingredient's effectiveness. It's about the regulatory framework governing your medication, the supply chain it travels through, and the price model that comes with each.

Why genetics belong in the cash-pay conversation

Both Foundayo and the compounded GLP-1 protocols start patients on a population-average titration schedule and adjust based on subjective tolerability. That works for many patients; it works less well for the fraction whose GLP-1 response is shaped by variants in GLP1R, FTO, MC4R, and TCF7L2 — or whose response to the GIP component of tirzepatide is shaped by GIPR rs1800437, the headline variant for differential GLP-1 response. The PlexusDx Precision Peptide Genetic Test maps 48 unique genes and 57 genetic variants across 14 health pathways, including 34 weight-management insights, and is delivered through the Peptide Pathways Report in the PlexusDx Results Portal. It's $298 standalone, or $99 as an add-on after the first month of any PlexusDx protocol. Adding it to a year on the Microdose protocol still totals $1,647 — well below the $3,338 standard Foundayo year. Neither Foundayo nor the platforms that dispense it perform this stratification step before titration; PlexusDx does, when the test is included.

Frequently asked questions

How much does Foundayo cost without insurance?

Foundayo costs $149/month for the 0.8 mg starter dose, $199/month for 2.5 mg, $299/month for 5.5 mg and 9 mg, and $299–$349/month for 14.5 mg and 17.2 mg depending on whether you refill within the 45-day purchase-offer window. The free Lilly Self-Pay Savings Card is required for these prices and is capped at 10 fills per calendar year through 12/31/2026.

Is Foundayo really $149 a month all year?

No. The $149 price is the starter-dose price for month one only. Most patients escalate to 5.5 mg or higher within three months, at which point the maintenance price is $299/month, rising to $349 at the two highest doses if the 45-day refill window is missed. Budgeting $149/month for a full year underestimates the real total by roughly $1,500.

What is a realistic 12-month cost projection for Foundayo without insurance?

About $3,338 on a standard escalation with on-time refills and the purchase offer, or up to $3,738 if the highest doses are filled at the $349 regular price. By comparison, a year on the PlexusDx Microdose GLP-1 Protocol is $1,548 flat at $129/month, and a year on Semaglutide Injection ranges from $2,148 to $2,748.

What happens if I miss the 45-day Foundayo refill window?

At the 14.5 mg and 17.2 mg doses, your monthly price increases from $299 to $349 — a $50 per-fill penalty. The rule does not apply to the 5.5 mg or 9 mg maintenance doses. PlexusDx protocol pricing carries no equivalent refill-window penalty.

Is Foundayo cheaper than compounded oral semaglutide or tirzepatide?

It depends on the dose. Foundayo's 0.8 mg starter at $149 is below the PlexusDx Semaglutide Oral entry tier of $249/mo, but Foundayo's $299–$349 maintenance band is in the same range or higher than several PlexusDx protocols. The PlexusDx Microdose GLP-1 Protocol at $129/month flat is the lowest cash-pay GLP-1 entry point in this comparison.

Does PlexusDx accept insurance for its weight management protocols?

No. PlexusDx is cash-pay in all 50 states with no membership fee. Pricing is all-inclusive of async provider consultation, prescription, compounded medication, and shipping. Five states require a scheduled live consultation rather than async intake.

Does Medicare cover Foundayo?

Not yet for most beneficiaries. The Medicare GLP-1 Bridge program may allow eligible Part D beneficiaries to access Foundayo at approximately $50/month starting as early as July 1, 2026, with the broader BALANCE Medicare Part D model launching January 2027. Cash-pay buyers without Medicare coverage are evaluating Foundayo against compounded alternatives like the PlexusDx protocols.

Foundayo Cost Without Insurance vs PlexusDx (2026): Cash-Pay GLP-1 Math | PlexusDx